Post-earnings recap
Reported
Wed, Aug 12, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
13%
Despite missing on EPS, Vaxcyte's stock rose by 8% following the earnings report. Investors may be reacting positively to management's commentary about ongoing development and future potential. The lack of revenue data and guidance suggests uncertainty, but the stock's rise indicates some confidence in the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.72 | N/A | -160.61% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism about the company's future. They emphasized their commitment to advancing their pipeline despite current setbacks.
Management highlighted ongoing development efforts and the importance of upcoming clinical milestones.
They acknowledged the challenges faced but expressed confidence in the long-term vision.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—